Clinical Trials
9 trialsNCT05853965 2026-05-18
BELI(E)VE
Universitätsklinikum Hamburg-Eppendorf
Phase 1/2 Recruiting
NCT04988555 2026-03-24
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Sumitomo Pharma America, Inc.
Phase 1/2 Recruiting
NCT04068597 2025-12-18
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
CellCentric Ltd.
Phase 1/2 Recruiting
NCT03732703 2025-02-14
MyDRUG
Multiple Myeloma Research Consortium
Phase 1/2 Completed
NCT03701321 2023-09-26
Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1/2 Withdrawn
NCT01794520 2023-04-10
Study Evaluating ABT-199 in Participants With Relapsed or Refractory Multiple Myeloma
AbbVie
Phase 1/2 Completed
NCT03312530 2023-02-28
A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma
Hoffmann-La Roche
Phase 1/2 Completed
NCT02265731 2021-08-02
Study Evaluating Venetoclax in Subjects With Hematological Malignancies
AbbVie
Phase 1/2 Completed
NCT03856112 2019-03-26
Ixazomib and Dexamethasone With or Without Venetoclax in Treating Patients With Non-t(11;14) Relapsed or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1/2 Withdrawn